Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
About one-third of oestrogen receptor alpha-positive breast cancer patients treated with tamoxifen relapse. Here we identify the nuclear receptor retinoic acid receptor alpha as a marker of tamoxifen resistance. Using quantitative mass spectrometry-based proteomics, we show that retinoic acid receptor alpha protein networks and levels differ in a tamoxifen-sensitive (MCF7) and a tamoxifen-resistant (LCC2) cell line. High intratumoural retinoic acid receptor alpha protein levels also correlate with reduced relapse-free survival in oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen solely. A similar retinoic acid receptor alpha expression pattern is seen in a comparable independent patient cohort. An oestrogen receptor alpha and retinoic acid receptor alpha ligand screening reveals that tamoxifen-resistant LCC2 cells have increased sensitivity to retinoic acid receptor alpha ligands and are less sensitive to oestrogen receptor alpha ligands compared with MCF7 cells. Our data indicate that retinoic acid receptor alpha may be a novel therapeutic target and a predictive factor for oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen. Many patients with breast cancer develop resistance to the drug tamoxifen and relapse. Here Johansson et al. identify the nuclear receptor retinoic acid receptor alpha (RARA) as a marker of tamoxifen resistance and show that RARA expression correlates negatively with relapse-free survival of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
The Proteomics Identifications (PRIDE) database and associated tools: status in 2013
Vizcaíno, J. A., Côté, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster, J. M., Griss, J., Alpi, E., Birim, M., Contell, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1262 · Cited by 1,918
REporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0354-x · Cited by 129
Forshed, J., Johansson, H. J., Pernemalm, M., Branca, R. M. M., Sandberg, A., & Lehtiö, J. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010264 · Cited by 32
Self-citation
Research works printed but not linked: 40
- Colditz, G. A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 90, 814–823 (1998). · DOI · Paper page
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005). · DOI · Paper page
- Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631–643 (2009). · DOI · Paper page
- Michalides, R. et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5, 597–605 (2004). · DOI · Paper page
- van Agthoven, T. et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J. Clin. Oncol. 27, 542–549 (2009). · DOI · Paper page
- van Agthoven, T. et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res. Treat. 114, 23–30 (2009). · DOI
- van Agthoven, T., Godinho, M. F., Wulfkuhle, J. D., Petricoin, E. F. 3rd & Dorssers, L. C. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int. J. Cancer 131, 1998–2007 (2012). · DOI
- Linderholm, B. et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 18, 1423–1431 (2000). · DOI · Paper page
- Linderholm, B. K. et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61, 2256–2260 (2001).
- Aesoy, R. et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 6, 1630–1638 (2008). · DOI
- Hua, S., Kittler, R. & White, K. P. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259–1271 (2009). · DOI · Paper page
- Ross-Innes, C. S. et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 24, 171–182 (2010). · DOI · Paper page
- Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R. & Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug. Discov. 6, 793–810 (2007). · DOI · Paper page
- Decensi, A. et al. Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J. Clin. Oncol. 27, 3749–3756 (2009). · DOI
- Gonzalez-Angulo, A. M., Hennessy, B. T. & Mills, G. B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777–2783 (2010). · DOI · Paper page
- Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001). · DOI · Paper page
- Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800 (2009). · DOI · Paper page
- Symmans, W. F. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28, 4111–4119 (2010). · DOI · Paper page
- Altelaar, A. F., Munoz, J. & Heck, A. J. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Genet. 14, 35–48 (2013). · DOI · Paper page
- Brunner, N. et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53, 3229–3232 (1993).
- Linderholm, B., Lindh, B., Tavelin, B., Grankvist, K. & Henriksson, R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int. J. Cancer 89, 51–62 (2000). · DOI · Paper page
- Hua, S. et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol. Syst. Biol. 4, 188 (2008). · DOI · Paper page
- Saito, A. et al. All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology 148, 1412–1423 (2007). · DOI · Paper page
- Godinho, M. F. et al. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br. J. Cancer 107, 947–955 (2012). · DOI
- Lim, J. S., Park, S. H. & Jang, K. L. All-trans retinoic acid induces cellular senescence by up-regulating levels of p16 and p21 via promoter hypomethylation. Biochem. Biophys. Res. Commun. 412, 500–505 (2011). · DOI
- Park, S. H., Lim, J. S. & Jang, K. L. All-trans retinoic acid induces cellular senescence via upregulation of p16, p21, and p27. Cancer Lett. 310, 232–239 (2011). · DOI
- Lonard, D. M. & O'Malley, B. W. The expanding cosmos of nuclear receptor coactivators. Cell 125, 411–414 (2006). · DOI · Paper page
- Tanaka, T., Rodriguez de la Concepcion, M. L. & De Luca, L. M. Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem. Pharmacol. 61, 1347–1355 (2001). · DOI
- Laursen, K. B., Wong, P. M. & Gudas, L. J. Epigenetic regulation by RARalpha maintains ligand-independent transcriptional activity. Nucleic. Acids. Res. 40, 102–115 (2012). · DOI
- Hurtado, A. et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663–666 (2008). · DOI · Paper page
- Germain, P. et al. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem. Biol. 16, 479–489 (2009). · DOI
- Lu, Y., Bertran, S., Samuels, T. A., Mira-y-Lopez, R. & Farias, E. F. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. Oncogene 29, 3665–3676 (2010). · DOI
- Hirokawa, Y., Arnold, M., Nakajima, H., Zalcberg, J. & Maruta, H. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol. Ther. 4, 956–960 (2005). · DOI
- Scott, S. M., Brown, M. & Come, S. E. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert. Opin. Drug. Saf. 10, 819–826 (2011). · DOI
- Hu, X. F. et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer 55, 873–876 (1993). · DOI
- Veronesi, U. et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17, 1065–1071 (2006). · DOI · Paper page
- Connolly, R., Nguyen, N. K. & Sukumar, S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin. Cancer Res. 19, 1651–1659 (2013). · DOI · Paper page
- Eriksson, H. et al. Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms. Proteomics 8, 3008–3018 (2008). · DOI · Paper page
- Sanchez, B. C. et al. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Eur. J. Cancer 46, 1580–1587 (2010). · DOI
- Linderholm, B. K., Hellborg, H., Johansson, U., Skoog, L. & Lehtio, J. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. Breast. Cancer Res. Treat. 125, 457–465 (2011). · doi:10.1007/s10549-010-1252-x
Cited by
Mass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
Anderson, J. D., Johansson, H. J., Graham, C. S., Vesterlund, M., Pham, M. T., Bramlett, C. S., Montgomery, E. N., Mellema, M. S., Bardini, R. L., Contreras, Z., et al. (2016) · Stem Cells · doi:10.1002/stem.2298 · Cited by 528
Self-citationAldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells
Vassalli, G. (2019) · Stem Cells International · doi:10.1155/2019/3904645 · Cited by 300
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138
Metadata
- Authors
- Johansson, H. J., Sanchez, B. C., Mundt, F., Forshed, J., Kovacs, A., Panizza, E., Hultin-Rosenberg, L., Lundgren, B., Martens, U., Máthé, G., Yakhini, Z., Helou, K., Krawiec, K., Kanter, L., Hjerpe, A., Stål, O., Linderholm, B. K., & Lehtiö, J.
- Venue
- Nature Communications
- Published
- 2013-07-19
- Volume
- 4
- Issue
- 1
- Pages
- 2175-2175
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2027444207
- Cited by
- 60
- References
- 5
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. https://app.cochat.ai/papers/10.1038/ncomms3175
- The paper
- Johansson, H. J., Sanchez, B. C., Mundt, F., Forshed, J., Kovacs, A., Panizza, E., Hultin-Rosenberg, L., Lundgren, B., Martens, U., Máthé, G., Yakhini, Z., Helou, K., Krawiec, K., Kanter, L., Hjerpe, A., Stål, O., Linderholm, B. K., & Lehtiö, J. (2013). Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nature Communications. https://doi.org/10.1038/ncomms3175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.